Grail Inc. | Small-cap | Healthcare
$44.85
-4.00%
| Grail Stock Comparison:
Grail vs Thermo FisherGrail vs DanaherGrail vs Twist BioscienceGrail vs Opko HealthGrail vs NeogenGrail vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 125.6M
Gross Profit -78.0M -62.12%
Operating Income -768.2M -611.67%
Net Income -2.0B -1,613.92%
EPS (Diluted) -$63.54

Balance Sheet Metrics

Total Assets 3.0B
Total Liabilities 479.9M
Shareholders Equity 2.5B
Debt to Equity 0.19

Cash Flow Metrics

Operating Cash Flow -2.0B
Free Cash Flow -582.4M

Revenue & Profitability Trend

Grail Income Statement From 2018 to 2024

Metric20242023202220192018
Revenue125.6M93.1M55.6M00
Cost of Goods Sold203.6M188.7M172.0M--
Gross Profit-78.0M-95.6M-116.4M--
Operating Expenses690.2M701.3M626.0M255.7M287.5M
Operating Income-768.2M-796.9M-742.5M-255.7M-287.5M
Pre-tax Income-2.2B-1.5B-5.4B-245.0M-275.2M
Income Tax-135.4M-224.0M-42.3M-195.0K485.0K
Net Income-2.0B-1.3B-5.4B-244.9M-275.7M
EPS (Diluted)-$63.54-$41.34-$173.87-$7.89-$8.88

Income Statement Trend

Grail Balance Sheet From 2018 to 2024

Metric20242023202220192018
Assets
Current Assets819.9M156.1M295.6M557.5M649.2M
Non-Current Assets2.2B3.8B4.6B78.0M37.6M
Total Assets3.0B3.9B4.9B635.5M686.8M
Liabilities
Current Liabilities76.9M163.6M134.9M44.9M74.2M
Non-Current Liabilities403.0M104.0M156.9M1.8B1.6B
Total Liabilities479.9M267.6M291.8M1.8B1.7B
Equity
Total Shareholders Equity2.5B3.6B4.6B-1.2B-1.0B

Balance Sheet Composition

Grail Cash Flow Statement From 2018 to 2024

Metric20242023202220192018
Operating Activities
Net Income-2.0B-1.5B-5.4B-244.9M-275.7M
Operating Cash Flow-2.0B-1.3B-5.3B-210.9M-250.9M
Investing Activities
Capital Expenditures-5.2M-12.9M-22.9M-3.2M-15.5M
Investing Cash Flow-551.0M-12.9M-22.9M133.0M-93.4M
Financing Activities
Dividends Paid-----
Financing Cash Flow1.2B463.8M604.8M157.3M297.8M
Free Cash Flow-582.4M-608.7M-584.2M-249.1M-225.2M

Cash Flow Trend

Grail Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -0.70
Forward P/E -3.39
Price to Book 0.61
Price to Sales 11.56
PEG Ratio -0.01

Profitability Ratios

Profit Margin -62.12%
Operating Margin -482.59%
Return on Equity -62.22%
Return on Assets -11.98%

Financial Health

Current Ratio 9.70
Debt to Equity 2.67

Per Share Data

EPS (TTM) -$59.59
Book Value per Share $68.38
Revenue per Share $4.00

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
gral1.5B-0.700.61-62.22%-62.12%2.67
Thermo Fisher 152.5B23.693.0913.70%15.19%69.23
Danaher 140.5B37.982.767.22%15.81%34.56
Twist Bioscience 2.2B-9.854.89-38.22%-54.98%18.25
Opko Health 1.0B-16.120.65-3.04%-5.66%37.58
Neogen 1.0B865.000.39-16.71%-53.56%33.61

Financial data is updated regularly. All figures are in the company's reporting currency.